Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus estimates.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
Shares of healthcare diagnostics company Labcorp Holdings (NYSE:LH)
fell 3.8% in the morning session after the company's third-quarter results, while beating headline estimates, revealed a miss on a key profitability metric and included guidance that failed to impress investors. The healthcare diagnostics company reported revenue of $3.56 billion, in line with Wall Street expectations, and an adjusted profit of $4.18 per share, which was 1% above consensus. However, investors looked past the top- and bottom-line beats to focus on other details. The company's adjusted EBITDA of $596.8 million missed analyst estimates. Furthermore, while Labcorp slightly raised its full-year adjusted earnings per share guidance, the modest revision appeared to underwhelm the market, which was likely anticipating a more robust outlook.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus estimates.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 13.9% return has trailed the S&P 500 by 18.8 percentage points.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) has emerged as a standout performer in the financial markets today, September 26, 2025, with its stock experiencing a dramatic surge. The significant uptick, which saw shares climb by over 52% in premarket trading and reach highs of 79% and 60.71% during Friday's session,
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Labcorp (NYSE:LH) and the rest of the testing & diagnostics services stocks fared in Q2.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
